Mineralys Therapeutics, Inc.
MLYSHeld by 7 specialist biotech funds
High Convergence7 funds opened new positions. Next phase3 readout (lorundrostat): Dec 2025. Short interest: 12.6% of float.
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.